Roflumilast Cream (ARQ-151) 0.15% and 0.3% Improved Burden of Signs and Symptoms in Adults With Chronic Plaque Psoriasis in a Phase 2b Study

Main Article Content

Leon Kircik
Mark Lebwohl
Kim Papp
Melinda Gooderham
Linda Stein Gold
Zoe Draelos
Steven Kempers
Stephen Tyring
Lorne Albrecht
Marni Wiseman
Laura Ferris
Kathleen Smith
Robert Higham
Lynn Navale
Howard Welgus
David Berk


Psoriasis, Chronic Plaque Psoriasis, PDE-4 Inhibitor, Topical, Roflumilast


Abstract not available.


1. Griffiths CE, Barker JN. Lancet2007;370:263-271.

2. BoehnckeW-H, Schön MP. Lancet2015;386:983-994.

3. Papp KA, et al. J Drugs Dermatol2020;19:734-740.

4. LebwohlMG, et al. N EnglJ Med 2020;383:229-239.

5. LebwohlM, et al. Int J Dermatol2014;53:714-722.

6. Strober BE, et al. Value Health 2013;16:1014-1022.

7. Strober B, et al. Int J Dermatol2016;55:e147-e155.

8. Finlay AY, Khan GK. Clin Exp Dermatol1994;19:210-216.

Most read articles by the same author(s)

<< < 6 7 8 9 10 11 12 13 14 15 > >>